在体外药效学模型中，将利奈唑胺和万古霉素单独及与利福平联合使用，与莫西沙星相比，用于对抗一株耐多药和耐万古霉素的肺炎链球菌菌株。
Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model.
作者信息
Cha Raymond, Rybak Michael J
机构信息
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit Receiving Hospital, Detroit, Michigan 48201, USA.
出版信息
Antimicrob Agents Chemother. 2003 Jun;47(6):1984-7. doi: 10.1128/AAC.47.6.1984-1987.2003.
Abstract
Potential alternatives, including linezolid, adjunctive rifampin, and moxifloxacin, were evaluated against vancomycin-tolerant (P9802-020) and vancomycin-susceptible clinical isolates of Streptococcus pneumoniae in an in vitro pharmacodynamic model. Vancomycin exhibited maximal killing of 2-log(10) CFU/ml against P9802-020. Linezolid, moxifloxacin, and linezolid plus rifampin exhibited 99.9% killing against both isolates. These alternatives should be considered for further evaluation against vancomycin-tolerant S. pneumoniae.
摘要
在体外药效学模型中，对利奈唑胺、辅助性利福平以及莫西沙星等潜在替代药物针对耐万古霉素（P9802 - 020）和对万古霉素敏感的肺炎链球菌临床分离株进行了评估。万古霉素对P9802 - 020显示出最大杀菌效果为2-log(10) CFU/ml。利奈唑胺、莫西沙星以及利奈唑胺加rifampin对两种分离株的杀菌率均达到99.9%。对于耐万古霉素的肺炎链球菌，应考虑对这些替代药物进行进一步评估。
相似文献
1
Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model.在体外药效学模型中，将利奈唑胺和万古霉素单独及与利福平联合使用，与莫西沙星相比，用于对抗一株耐多药和耐万古霉素的肺炎链球菌菌株。
Antimicrob Agents Chemother. 2003 Jun;47(6):1984-7. doi: 10.1128/AAC.47.6.1984-1987.2003.
2
Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.在体外药效学模型中，利奈唑胺、左氧氟沙星和万古霉素对耐万古霉素和耐氟喹诺酮肺炎链球菌的作用
Pharmacotherapy. 2003 Dec;23(12):1531-7. doi: 10.1592/phco.23.15.1531.31964.
3
In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.利奈唑胺对耐万古霉素肠球菌、耐甲氧西林金黄色葡萄球菌和耐青霉素肺炎链球菌的体外活性。
Diagn Microbiol Infect Dis. 1999 Jun;34(2):119-22. doi: 10.1016/s0732-8893(99)00016-4.
4
Bacteriostatic or bactericidal effect of linezolid against multiresistant Streptococcus pneumoniae.
New Microbiol. 2008 Jul;31(3):363-70.
5
Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.在使用模拟心内膜赘生物的体外药效学模型以及使用大蜡螟幼虫的体内存活试验中，达托霉素或利奈唑胺与利福平或庆大霉素联合使用对形成生物膜的粪肠球菌或屎肠球菌的活性。
Antimicrob Agents Chemother. 2014 Aug;58(8):4612-20. doi: 10.1128/AAC.02790-13. Epub 2014 May 27.
6
In vivo pharmacodynamics of a new oxazolidinone (linezolid).一种新型恶唑烷酮类药物（利奈唑胺）的体内药效学
Antimicrob Agents Chemother. 2002 Nov;46(11):3484-9. doi: 10.1128/AAC.46.11.3484-3489.2002.
7
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.早期、高剂量利奈唑胺对万古霉素中介耐药肠球菌的药效学研究，该肠球菌具有升高的 MIC 值和预先存在的基因突变。
J Antimicrob Chemother. 2012 Sep;67(9):2182-90. doi: 10.1093/jac/dks201. Epub 2012 Jun 8.
8
Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.在中性粒细胞减少症小鼠的对侧大腿中分别注射 10(5) 和 10(7) CFU 的金黄色葡萄球菌和肺炎链球菌时，头孢洛林、达托霉素、利奈唑胺和万古霉素的接种体效应。
Antimicrob Agents Chemother. 2013 Mar;57(3):1434-41. doi: 10.1128/AAC.00362-12. Epub 2013 Jan 7.
9
Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae.恶唑烷酮类药物AZD2563与利奈唑胺对近期北美分离出的部分肺炎链球菌菌株的活性比较
Antimicrob Agents Chemother. 2002 Sep;46(9):3094-5. doi: 10.1128/AAC.46.9.3094-3095.2002.
10
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.利奈唑胺与万古霉素、庆大霉素、环丙沙星、夫西地酸和利福平联合应用对金黄色葡萄球菌的体外杀菌活性。
Antimicrob Agents Chemother. 2003 Jan;47(1):418-20. doi: 10.1128/AAC.47.1.418-420.2003.
引用本文的文献
1
Development and Validation of an HPLC-UV Method for Quantitation of Linezolid: Application to Resistance Study Using in vitro PK/PD Model.一种用于定量利奈唑胺的高效液相色谱-紫外检测法的建立与验证：在体外药代动力学/药效学模型用于耐药性研究中的应用
Infect Drug Resist. 2021 Dec 1;14:5089-5098. doi: 10.2147/IDR.S343200. eCollection 2021.
2
In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.抗传染性药物研发中的体外药代动力学/药效学模型：以结核病为例。
Future Med Chem. 2010 Aug;2(8):1355-69. doi: 10.4155/fmc.10.224.
3
Pharmacological issues of linezolid: an updated critical review.利奈唑胺的药理学问题：更新的批判性评价。
Clin Pharmacokinet. 2010 Jul;49(7):439-47. doi: 10.2165/11319960-000000000-00000.
4
Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.体外模型中影响对利奈唑胺耐药性出现的药代动力学/药效学因素。
Antimicrob Agents Chemother. 2007 Apr;51(4):1287-92. doi: 10.1128/AAC.01194-06. Epub 2007 Jan 22.
本文引用的文献
1
In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.在体外药效学模型中，单独及与多种抗菌药物联合使用时，奎奴普丁-达福普汀和头孢吡肟对耐多药葡萄球菌和肠球菌的体外活性。
Antimicrob Agents Chemother. 2002 Aug;46(8):2606-12. doi: 10.1128/AAC.46.8.2606-2612.2002.
2
Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.肺炎链球菌对氟喹诺酮类药物的耐药性增加：2000年香港多中心研究结果
J Antimicrob Chemother. 2001 Nov;48(5):659-65. doi: 10.1093/jac/48.5.659.
3
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.莫西沙星、左氧氟沙星和司帕沙星对肺炎链球菌的药效学
J Antimicrob Chemother. 2001 Jun;47(6):811-8. doi: 10.1093/jac/47.6.811.
4
Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.新型氟喹诺酮类药物对耐环丙沙星肺炎链球菌的活性。
Antimicrob Agents Chemother. 2001 Jun;45(6):1654-9. doi: 10.1128/AAC.45.6.1654-1659.2001.
5
Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.耐青霉素肺炎链球菌：莫西沙星活性综述
Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S22-9. doi: 10.1086/319372.
6
Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae.肺炎链球菌中抗菌药物的使用与耐药性变化
Emerg Infect Dis. 2000 Sep-Oct;6(5):552-6. doi: 10.3201/eid0605.000519.
7
Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis.从一名复发性脑膜炎患者的脑脊液中分离并鉴定耐万古霉素肺炎链球菌。
J Infect Dis. 2000 Jan;181(1):369-73. doi: 10.1086/315216.
8
Fluoroquinolone resistance in Streptococcus pneumoniae.肺炎链球菌对氟喹诺酮类药物的耐药性
N Engl J Med. 1999 Nov 11;341(20):1546-7; author reply 1547-8. doi: 10.1056/nejm199911113412013.
9
Geographic variation in penicillin resistance in Streptococcus pneumoniae--selected sites, United States, 1997.1997年美国部分地区肺炎链球菌对青霉素耐药性的地理差异
MMWR Morb Mortal Wkly Rep. 1999 Aug 6;48(30):656-61.
10
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.加拿大肺炎链球菌对氟喹诺酮类药物的敏感性降低。加拿大细菌监测网络。
N Engl J Med. 1999 Jul 22;341(4):233-9. doi: 10.1056/NEJM199907223410403.
Zotero 插件